Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT UBC Medical Indonesia TbkISX:LABS +0.58%2 Debt-to-Equity is 0.15 as of Jun. 2026. GuruFocus rates ISX:LABS with a GF Score™ of 2/100. The stock has 2 warning signs investors should review. Among 698 Medical Devices & Instruments companies, PT UBC Medical Indonesia Tbk ranks worse than 143266.33% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PT UBC Medical Indonesia Tbk's Debt-to-Equity or its related term are showing as below:
ISX:LABS's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.24 * Ranked among companies with meaningful Debt-to-Equity only.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PT UBC Medical Indonesia Tbk Debt-to-Equity Related Terms
PT UBC Medical Indonesia Tbk Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:LABS vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, PT UBC Medical Indonesia Tbk's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT UBC Medical Indonesia Tbk Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT UBC Medical Indonesia Tbk's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PT UBC Medical Indonesia Tbk's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT UBC Medical Indonesia Tbk (ISX:LABS) has a Debt-to-Equity of 0.15 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PT UBC Medical Indonesia Tbk and its competitors. According to the industry distribution chart, PT UBC Medical Indonesia Tbk ranks #999999 out of 698 companies in the Medical Devices & Instruments industry.
Is PT UBC Medical Indonesia Tbk's Debt-to-Equity too high?
PT UBC Medical Indonesia Tbk's current Debt-to-Equity is 0.15. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. PT UBC Medical Indonesia Tbk's value of 0.15 is 37.5% below this industry median. Based on the distribution chart, PT UBC Medical Indonesia Tbk ranks #999999 out of 698 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PT UBC Medical Indonesia Tbk has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does PT UBC Medical Indonesia Tbk's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, PT UBC Medical Indonesia Tbk ranks #999999 out of 698 companies for Debt-to-Equity. This places PT UBC Medical Indonesia Tbk in the lower half of its industry. The industry median Debt-to-Equity is 0.24. PT UBC Medical Indonesia Tbk's value of 0.15 is 37.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT UBC Medical Indonesia Tbk's current Debt-to-Equity of 0.15 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PT UBC Medical Indonesia Tbk and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT UBC Medical Indonesia Tbk's current Debt-to-Equity is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT UBC Medical Indonesia Tbk stock overvalued right now?
PT UBC Medical Indonesia Tbk (ISX:LABS) has a current Debt-to-Equity of 0.15. The current Debt-to-Equity is 0.15 and 37.5% below the Medical Devices & Instruments industry median of 0.24. PT UBC Medical Indonesia Tbk's overall GF Score™ is 2/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PT UBC Medical Indonesia Tbk (ISX:LABS), the current Debt-to-Equity is 0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT UBC Medical Indonesia Tbk is a distribution company. It engages in wholesale of Laboratory Equipment, Pharmaceutical Equipment, and Medical Equipment for Humans and animals, which includes the wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment. It divides its main marketed medical equipment products into two categories Instruments, in the form of equipment, machines, and analyzers, are used in laboratories. The function of instruments is to process specimens or biological samples to measure and examine the levels of certain substances/contents; and Consumables include single-use medical devices used for treatment or health examinations and Reagents include chemical reagents used in laboratory tests to detect, measure, examine, & produce other substances.
2GF Score
Get the complete analysis for ISX:LABS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:LABS has been successfully added to your 
